News | Radiology Business | April 10, 2023

ASTRO issued the following statement regarding the recent final rule from the CMS that revises the Medicare Advantage prior authorization process 

ASTRO issued the following statement regarding the recent final rule from the CMS that revises the Medicare Advantage prior authorization process

Getty Images


April 10, 2023 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Geraldine M. Jacobson, MD, MBA, MPH, FASTRO, Board of Directors Chair, in response to the recent final rule from the Centers for Medicare and Medicaid Services (CMS) that revises the Medicare Advantage prior authorization process: 

"ASTRO applauds this final rule from CMS, which is a major step in reforming the broken, burdensome prior authorization system. Changes that increase transparency, reduce care disruptions and improve coverage criteria guidelines used by Medicare Advantage plans will bring much-needed relief to physicians and our patients with cancer. We appreciate that CMS addressed an array of concerns raised by ASTRO, the radiation oncology community and physicians nationwide. 

The delays and interference associated with prior authorization are unnecessarily burdensome for radiation oncologists, who face the most significant prior authorization hurdles of any medical specialty. Based on ASTRO research, 90% of radiation oncology practices report that prior authorization delayed their patients’ access to life-saving cancer treatments, and a majority say the average delay lasts a week or longer. 

While we are optimistic about these reforms, we also urge CMS to hold insurance companies accountable for following the new requirements. We also eagerly await additional rulemaking to address the substantial administrative burden created by prior authorization. Further changes such as streamlining the approval process and establishing determination timelines will be necessary to truly repair this broken system.” 

For more information: www.astro.org 

Find more ASTRO23 content here 


Related Content

News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
Sponsored Content | Videos | Radiology Business

Radiology departments have many different needs and face a wide variety of challenges that can impact their departments ...

Time November 11, 2025
arrow
News | Interventional Radiology

Nov. 10, 2025 — Interventional radiologists (IRs) that almost exclusively practice in their specialty provide more ...

Time November 11, 2025
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
News | Lung Imaging

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...

Time November 07, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | Stereotactic Body Radiation Therapy (SBRT) | American Society for Radiation Oncology

Sept. 29, 2025 — A new clinical trial report finds that stereotactic radiation therapy offers long-term survival ...

Time October 15, 2025
arrow
Subscribe Now